Privately owned Oxford Nanopore offers a range of tools and and instruments based on a proprietary nanopore-based DNA and RNA sequencing technology.
Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
Oxford BioDynamics has developed a platform for discovering, evaluating, validating, and monitoring a unique class of epigenetic biomarkers.
The company intends to use the proceeds for, among other things, investigating the use of blockchain technology in medicine and biotechnology.
Centrillion Technologies received a multimillion US dollar investment from WeDoctor while Centrillion Technologies Taiwan obtained a strategic investment from Arm IoT Fund.
With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.
Built by two of the creators of Nextflow, former Techstars company Lifebit makes scaleable genomic analysis technology that runs in the cloud.
Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The Slovenia-based firm will use the funds to develop its Health Intelligence platform, expand into Asian markets, and open an office in the UK.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.